Home › All Companies › BCRX › Annual Report

BIOCRYST PHARMACEUTICALS INC (BCRX) — Annual Report

AI-Powered SEC Filing Analysis

← All BCRX filings
Latest Annual Report Filed: 2026-02-26

Key Insights

  • BioCryst Pharmaceuticals reported a decline in product revenues for 2025 compared to the prior year, indicating potential challenges in its key commercial products.
  • The company recorded an increase in license and other revenues, suggesting progress in its licensing and collaboration agreements, which could provide additional revenue streams.
  • BioCryst Pharmaceuticals divested its Irish subsidiary, BioCryst Ireland, in 2025, potentially streamlining its operations and focusing on core business activities.
Sentiment: Neutral Significance: 5/10
View Original Filing →

Want the newest filings?

This analysis covers the filing from 2026-02-26. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Other reports for BIOCRYST PHARMACEUTICALS INC

Current Report Quarterly Report Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.